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S U M M A R Y
The aim of this study was to evaluate the application of direct disk diffusion (DDD) testing to respiratory
tract specimens for the prediction of the antimicrobial susceptibility proﬁle. DDD was performed on 144
specimens containing P. aeruginosa and the disk diffusion test was used as reference method. Agreement
with the reference method was 77.8% for amikacin, 69.4% for cefepime, 86.1% for levoﬂoxacin, 87.5% for
meropenem, and 62.5% for piperacillin/tazobactam. Very major errors were observed for all agents,
except levoﬂoxacin. Our study showed that DDD results are inaccurate and may lead to errors in early
decision-making regarding antibiotic therapy for lower respiratory tract infections.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Pseudomonas aeruginosa is the leading cause of respiratory tract
infections among hospitalized patients, mainly ventilator-associ-
ated pneumonia (VAP) in the intensive care unit.1 Acute infections,
such as VAP, are invasive and cytotoxic, and frequently result in
systemic infection, septic shock, and high rates of mortality.
Correct antibiotic therapy is essential for patient survival. In this
context, feasible and accurate susceptibility tests become critically
important for patient management and as a guide to therapeutic
approaches.2,3
Direct susceptibility tests have been applied to predict the
antimicrobial proﬁle of specimens from the lower respiratory tract
using the E-test. There are, however, no studies using the disk
diffusion method for this purpose.2,4–8
The objective of this study was to evaluate the agreement and
discrepancies of direct disk diffusion (DDD) testing applied to
respiratory tract specimens, focusing on P. aeruginosa isolates.§ This work was presented in part as a poster at the 24th Meeting of the European
Society of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 10–13,
2014.
* Corresponding author.
E-mail address: leandro.reus@gmail.com (L.R.R. Perez).
http://dx.doi.org/10.1016/j.ijid.2014.05.010
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).2. Materials and methods
Three hundred twenty-six respiratory tract samples from
patients admitted to the Hospital Ma˜e de Deus, Porto Alegre,
Brazil, between April and December 2012, were included in this
study. Smears were prepared, and specimens presenting Gram-
negative bacilli after microscopic examination were considered
eligible for the study.
A drop of sample (approximately 20 ml) was spread with a
sterile swab directly onto the surface of Mueller–Hinton agar
plates; from this point, we followed the procedures of the Clinical
and Laboratory Standards Institute (CLSI, 2013).9 Disks containing
30 mg amikacin, 30 mg cefepime, 5 mg levoﬂoxacin, 10 mg
meropenem, and 100/10 mg piperacillin/tazobactam were placed
directly onto the plates; these were incubated at 35 8C for 18 h. The
diameters of the inhibition zones were read. Escherichia coli ATCC
25922 and P. aeruginosa ATCC 27853 were used as control strains.
After these readings, the microorganisms that had grown on the
Mueller–Hinton agar plates were identiﬁed using MicroScan
WalkAway 96SI and Negative Combo 44 panel (Dade Behring,
Sacramento, CA, USA).
The results of DDD were compared to those obtained after
isolation of P. aeruginosa followed by the conventional disk
diffusion method (reference) in terms of categorical agreementsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Categorical agreement and discrepancies for antimicrobial agents tested on the
Pseudomonas aeruginosa isolates from the 144 distinct clinical specimens evaluated
Antimicrobial agent Number of categorical agreements and
discrepancies (%)
Agreement Minor
error
Major
error
Very
major
error
Amikacin 112 (77.8) 8 (5.5%) 10 (6.9) 14 (9.7)
Cefepime 100 (69.4) 32 (22.2) 8 (5.5) 4 (2.8)
Levoﬂoxacin 124 (86.1) 8 (5.5) 12 (8.3) 0
Meropenem 126 (87.5) 10 (6.9) 6 (4.1) 2 (1.4)
Piperacillin/tazobactam 90 (62.5) 22 (15.3) 24 (16.7) 8 (5.5)
Total 552 (76.7) 80 (11.1) 60 (8.3) 28 (3.9)
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involving an intermediate result; a major discrepancy was deﬁned
as an isolate that was determined to be resistant by DDD and
susceptible by the reference method; a very major discrepancy was
deﬁned as an isolate that was determined to be susceptible by DDD
and resistant by the standard method.10
3. Results
The presence of P. aeruginosa was veriﬁed in 44.2% (144/326) of
the samples. Based on the reference method, the resistance rates
were: 41.7% (60/144) to amikacin, 65.3% (94/144) to cefepime,
52.8% (76/144) to levoﬂoxacin, 61.1% (88/144) to meropenem, and
34.7% (50/144) to piperacillin/tazobactam. The overall agreement
achieved between the direct test and the reference test was 76.7%
(552/720 antibiotic–organism combinations).
Eighty minor errors (11.1%; 80/720), 60 major errors (8.3%; 60/
720), and 28 very major errors (3.9%; 28/720) occurred. Minor and
major errors occurred for all ﬁve antibiotics evaluated, while very
major errors involved all antibiotics except levoﬂoxacin. Table 1
shows the details of the individual antimicrobials for the 144
respiratory specimens containing P. aeruginosa evaluated.
In this study, there was no case in which the DDD resistance
could not be read due to scarce bacterial growth.
4. Discussion
Pseudomonas aeruginosa is the most frequent pathogen isolated
from respiratory tract secretions, and preliminary information
regarding antimicrobial susceptibility should be obtained as soon
as possible.1,4
It is of note that most studies have evaluated the use of the Etest
as a useful tool to provide results from direct susceptibility
testing.2,4–8 However, disk diffusion could be an alternative
method for this purpose as it is rapid, cheaper, and more feasible
for most microbiology laboratories.
In the study by Cercenado et al.,5 the overall agreement
achieved for direct Etest susceptibility in relation to broth
microdilution for quantitative culture of lower respiratory tract
secretions was 96.1%. It is important to note that a high number of
Staphylococcus aureus isolates (>45% of the microorganisms) were
present in that study, and there was total agreement for S. aureus
for all antimicrobials evaluated in monomicrobial culture, which
may explain the high accuracy achieved. Furthermore, all errorsobserved by Cercenado et al., including all cases of very major
error, were due to results for P. aeruginosa.
In studies conducted by Zebouh et al.,7,8 direct Etest results
were evaluated for P. aeruginosa isolates from respiratory speci-
mens collected from cystic ﬁbrosis patients. Despite the good
agreement obtained (direct susceptibility testing was as accurate
as the standard method when P. aeruginosa was the sole pathogen
present), the authors indicated the failure to detect low bacterial
density in mixed culture.
In contrast to the studies using Etest strips,4,5,8 our results
showed an unsatisfactory level of agreement between DDD and the
reference method. Very major errors were more notable with
amikacin (9.7%; 14/144) and piperacillin/tazobactam (5.5%; 8/
144). Moreover, minor and major errors were observed for all
agents, similarly to the study by Cercenado et al.5 Although some
studies have shown a good correlation of direct susceptibility
testing with the reference method, our results showed a limited
agreement (agreement <80%), mainly for amikacin, cefepime, and
piperacillin/tazobactam.
In conclusion, in this study we evaluated a considerable number
of P. aeruginosa isolates and our results indicated that DDD is
inaccurate for the prediction of the antimicrobial susceptibility
proﬁle and may lead to errors in selecting therapeutic options for
the treatment of Pseudomonas pneumonia.
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